Jove
Visualize
Contact Us

Related Experiment Videos

Thalidomide in Behçet's disease.

L P C Shek1, D L C Lim

  • 1Department of Paediatrics, National University of Singapore, Singapore. paeshekl@nus.edu.sg

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|March 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Income disparity in school readiness and the mediating role of perinatal maternal mental health: a longitudinal birth cohort study.

Epidemiology and psychiatric sciences·2021
Same author

Maternal hyperglycemia in singleton pregnancies conceived by IVF may be modified by first-trimester BMI.

Human reproduction (Oxford, England)·2017
Same author

Fixed drug eruption caused by piperacillin-tazobactam.

Journal of investigational allergology & clinical immunology·2013
Same author

Diagnostic tests for food allergy.

Singapore medical journal·2010
Same author

Humoral and cellular responses to cow milk proteins in patients with milk-induced IgE-mediated and non-IgE-mediated disorders.

Allergy·2005
Same author

The prevalence of asthma and allergies in Singapore; data from two ISAAC surveys seven years apart.

Archives of disease in childhood·2004
Same journal

Corrigendum to 'A new perspective on targeting pulmonary arterial hypertension: Programmed cell death pathways (Autophagy, Pyroptosis, Ferroptosis)' [Biomed. Pharmacother. 181 (2024) 117706].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Inhibition of the ZEB1-BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

From DNA-encoded library (DEL) screening to in vivo validation: LILRB4 (ILT3)-targeted small molecules reprograms myeloid immune suppression.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Wnt activation during epileptogenesis prevents pathological immature dentate granule cell morphological changes in animal models of unilateral and bilateral temporal lobe epilepsy.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Protective effects of ACF210, a dual GLP-1/APJ receptor agonist, against cardiovascular-kidney-metabolic syndrome induced by T2D.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Behçet

Area of Science:

  • Rheumatology and Immunology
  • Dermatology
  • Ophthalmology

Background:

  • Behçet's disease is a chronic, relapsing multisystem disorder of unknown cause.
  • It typically presents with oral and genital ulcers, and eye inflammation (uveitis).
  • The condition shows geographic clustering, particularly in Mediterranean and East Asian regions.

Purpose of the Study:

  • To review the characteristics of Behçet's disease.
  • To discuss the current treatment strategies for Behçet's disease.
  • To evaluate the efficacy and role of thalidomide in managing Behçet's disease.

Main Methods:

  • This is a review article.
  • Information was gathered from existing literature on Behçet's disease and thalidomide treatment.

Related Experiment Videos

  • The review synthesizes current knowledge on the disease and therapeutic options.

    • Main Results:

    • Behçet's disease is characterized by recurrent, debilitating lesions.
    • Standard treatments include steroids, immunomodulators, and immunosuppressives.
    • Thalidomide has demonstrated some success in treating recalcitrant cases.

    Conclusions:

    • Behçet's disease requires comprehensive management due to its multisystemic nature.
    • Thalidomide offers a potential therapeutic option for specific manifestations of Behçet's disease.
    • Further research may elucidate optimal use of thalidomide in Behçet's disease management.